Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J. Asnacios A, et al. Among authors: fartoux l. Cancer. 2008 Jun 15;112(12):2733-9. doi: 10.1002/cncr.23489. Cancer. 2008. PMID: 18412149 Free article. Clinical Trial.
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.
André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W. André T, et al. Among authors: fartoux l. Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628. Br J Cancer. 2008. PMID: 19238628 Free PMC article. Clinical Trial.
[Therapeutic advances in hepatocellular carcinoma].
Poupon R, Fartoux L, Rosmorduc O. Poupon R, et al. Among authors: fartoux l. Bull Acad Natl Med. 2008 Jan;192(1):23-31; discussion 31-2. Bull Acad Natl Med. 2008. PMID: 18663979 Review. French.
Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O. Desbois-Mouthon C, et al. Among authors: fartoux l. Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25. Clin Cancer Res. 2009. PMID: 19706799
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators. Malka D, et al. Among authors: fartoux l. Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19. Lancet Oncol. 2014. PMID: 24852116 Free PMC article. Clinical Trial.
Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features.
Benabou E, Salamé Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chrétien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C. Benabou E, et al. Among authors: fartoux l. Cancer Lett. 2019 May 28;450:155-168. doi: 10.1016/j.canlet.2019.02.037. Epub 2019 Mar 6. Cancer Lett. 2019. PMID: 30849481 Free article.
HCC and NASH: how strong is the clinical demonstration?
Rosmorduc O, Fartoux L. Rosmorduc O, et al. Among authors: fartoux l. Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):202-8. doi: 10.1016/j.clinre.2011.12.011. Epub 2012 Feb 10. Clin Res Hepatol Gastroenterol. 2012. PMID: 22326764 Review.
62 results